非重症COVID-19患者接受(亚)治疗剂量抗凝药物的危害:帕多瓦省经验
这项回顾性分析纳入2020年2月至4月连续收治的324例COVID-19患者,其中240例接受预防剂量抗凝、84例接受更高剂量抗凝。预防剂量组主要出血或临床相关非主要出血复合终点发生率为6.9/100人月,更高剂量组为26.4/100人月(HR 3.89,95%CI 1.90-7.97)。作者结论不支持对非重症COVID-19患者给予(亚)治疗剂量抗凝。
要点
- 预防剂量组主要出血或临床相关非主要出血复合终点发生率为6.9/100人月。
- 更高剂量组该复合终点发生率为26.4/100人月,HR 3.89(95%CI 1.90-7.97)。
- 更高剂量组总死亡率未低于预防剂量组,作者结论不支持该策略。
核心结论
- 接受(亚)治疗剂量抗凝药物的患者相关出血事件发生率较高。
- 更高剂量组总死亡率与标准预防剂量组无差异且甚至更高。
- 作者结论不支持对非重症COVID-19患者给予(亚)治疗剂量抗凝药物。
研究设计与样本
- 回顾性分析,连续纳入2020年2月至4月收治的COVID-19患者。
- 共324例患者,240例接受预防剂量抗凝药物,84例接受更高剂量抗凝药物。
- 主要出血(MB)和临床相关非主要出血(CRNMB)取自患者病历,由独立委员会裁定。
主要发现
- 主要出血或临床相关非主要出血复合终点发生率:预防剂量组6.9/100人月 vs 更高剂量组26.4/100人月(HR 3.89,95%CI 1.90-7.97)。
- 总死亡率:预防剂量组12.2/100人月 vs 更高剂量组20.1/100人月。
临床怎么用
- 作者结论不支持对非重症COVID-19患者给予(亚)治疗剂量抗凝药物。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Coronavirus Disease 2019 (COVID-19) is responsible for a worldwide pandemic, with a high rate of morbidity and mortality. The increasing evidence of an associated relevant prothrombotic coagulopathy has resulted in an increasing use of antithrombotic doses higher than usual in COVID-19 patients. Information on the benefit/risk ratio of this approach is still lacking. OBJECTIVE: To assess the incidence of relevant bleeding complications in association with the antithrombotic strategy and its relationship with the amount of drug. METHODS: Consecutive COVID-19 patients admitted between February and April 2020 were included in a retrospective analysis. Major bleedings (MB) and clinically relevant non-major bleeding (CRNMB) were obtained from patient medical records and were adjudicated by an independent committee. RESULTS: Of the 324 patients who were recruited, 240 had been treated with prophylactic doses and 84 with higher doses of anticoagulants. The rate of the composite endpoint of MB or CRNMB was 6.9 per 100-person/months in patients who had been given prophylactic doses, and 26.4 per 100-person/months in those who had been prescribed higher doses (hazard ratio, 3.89; 95% confidence interval, 1.90-7.97). The corresponding rates for overall mortality were 12.2 and 20.1 per 100-person/months, respectively. CONCLUSIONS: The rate of relevant bleeding events was high in patients treated with (sub)therapeutic doses of anticoagulants. In the latter group, overall mortality did not differ from that of patients treated with standard prophylactic doses and was even higher. Our result does not support a strategy of giving (sub)therapeutic doses of anticoagulants in non-critically ill patients with COVID-19.
引用
- Pesavento R, Ceccato D, Pasquetto G, et al. The hazard of (sub)therapeutic doses of anticoagulants in non-critically ill patients with Covid-19: The Padua province experience. J Thromb Haemost. 2020. PMID: 32692874. doi:10.1111/jth.15022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。